0001104659-23-037370.txt : 20230328 0001104659-23-037370.hdr.sgml : 20230328 20230328070032 ACCESSION NUMBER: 0001104659-23-037370 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230327 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230328 DATE AS OF CHANGE: 20230328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Milestone Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001408443 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38899 FILM NUMBER: 23766113 BUSINESS ADDRESS: STREET 1: 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 CITY: MONTREAL STATE: A8 ZIP: H4M 2X6 BUSINESS PHONE: (514) 336-0444 MAIL ADDRESS: STREET 1: 1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420 CITY: MONTREAL STATE: A8 ZIP: H4M 2X6 8-K 1 tm2310615d2_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

March 27, 2023

MILESTONE PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

Québec		001-38899		Not applicable
(state or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1111 Dr. Frederik-Philips Boulevard,
Suite 420
Montréal, Québec CA				H4M 2X6
(Address of principal executive offices)				(Zip Code)

Registrant's telephone number, including area code: (514) 336-0444

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares		MIST		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Item 1.01.

Entry into a Material Definitive Agreement.

On March 27, 2023, Milestone Pharmaceuticals Inc. (the “Company”) entered into a Purchase and Sale Agreement (the “Royalty Purchase Agreement”) and a Note Purchase Agreement (the “Note Purchase Agreement”) with RTW Investments, LP and certain of its affiliates (collectively, “RTW”).

Pursuant to the Royalty Purchase Agreement, RTW agreed to purchase, following U.S. Food and Drug Administration (“FDA”) approval of etripamil (subject to certain conditions), in exchange for a purchase price of $75.0 million, the right to receive a tiered quarterly royalty payments (the “royalty interest”) on the annual net product sales of etripamil in the United States in an amount equal to: (i) 7% (the “Initial Tier Royalty”) of annual net sales up to $500 million, (ii) 4% of annual net sales greater than $500 million and less than or equal to $800 million, and (iii) 1% of annual net sales greater than $800 million. If certain revenue thresholds for aggregate annual net sales in the United States are not met, the Initial Tier Royalty will increase to 9.5% beginning on January 1 of the following calendar year until a subsequent sales threshold is attained, at which time the Initial Tier Royalty would revert back to 7%.

The Royalty Purchase Agreement contains various representations and warranties, covenants, indemnification obligations and other provisions customary for transactions of this nature, including the grant of a back-up security interests in the purchased royalties and certain assets related to etripamil and restrictions on the incurrence of additional indebtedness.

Pursuant to the Note Purchase Agreement, we will issue and sell $50 million principal amount of 6.0% Convertible Senior Notes due 2029 (the “2029 Convertible Notes”) to the holders, which is expected to close on March 29, 2023.

The 2029 Convertible Notes will be senior secured obligations and will be guaranteed on a senior secured basis by our wholly owned subsidiary, Milestone Pharmaceuticals USA, Inc. Interest at the annual rate of 6.0% is payable quarterly in cash or, at our option, payable in kind for the first three years. The maturity date for the 2029 Convertible Notes will be March 31, 2029 (the “Maturity Date”). The obligations under the 2029 Convertible Notes will be secured by substantially all of our and our subsidiary guarantor’s assets.

Each $1,000 of principal of the 2029 Convertible Notes (including any interest added thereto as payment in kind) is convertible into 191.0548 shares of our common shares, equivalent to an initial conversion price of approximately $5.23 per share, subject to customary anti-dilution adjustments. In addition, following a notice of redemption or certain corporate events that occur prior to the Maturity Date, we will, in certain circumstances, increase the conversion rate for a Holder who elects to convert its 2029 Convertible Notes in connection with such notice of redemption or corporate event.

Subject to specified conditions, on or after March 27, 2027, the 2029 Convertible Notes are redeemable by us if the closing sale price of the common shares exceeds 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which we provide notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption, at a redemption price equal to 100% of the principal amount of the 2029 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

The Note Purchase Agreement contains customary terms and covenants, including negative covenants, such as limitations on indebtedness, liens, disposition of royalty interest and mergers. The Note Purchase Agreement also contains customary events of default, including defaults related to payment compliance, material inaccuracy of representations and warranties, covenant compliance, bankruptcy and insolvency proceedings, cross defaults to certain other agreements, judgment default and certain clinical trial failures.

The descriptions of the Royalty Purchase Agreement and the Note Purchase Agreement are not complete and are qualified in its entirety by reference to the complete text of the Royalty Purchase Agreement and the Note Purchase Agreement, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2023.

Item 7.01.

Regulation FD Disclosure.

On March 28, 2023, the Company issued a press release announcing a transaction with RTW pursuant to the Royalty Purchase Agreement and Note Purchase Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01.

Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.	Description
99.1	Press release, dated March 28, 2023
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MILESTONE PHARMACEUTICALS INC.

Date: March 28, 2023	By:	/s/ Amit Hasija
		Amit Hasija
		Chief Financial Officer Principal Financial Officer

EX-99.1 2 tm2310615d2_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW
Investments to Support the Advancement of Etripamil for PSVT

- Proceeds from strategic financing together with year-end cash resources expected to
fund operations into mid-2025 including etripamil NDA submission and launch in PSVT

- The combination of etripamil's strong clinical results with this strategic financing lays the
foundation to deliver a therapy that empowers patients to treat supraventricular
tachycardia attacks outside the emergency department

Montreal and Charlotte, N.C., Mar. 28, 2023 --Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has entered into a $125 million strategic funding agreement with existing shareholder, RTW Investments, LP and certain of its affiliates (“RTW”). Proceeds from this tailored financing, together with $64.6 million of cash, cash equivalents and short-term investments as of December 31, 2022, are expected to fund Milestone’s operations into the middle of 2025, including the potential approval and launch of etripamil. Etripamil is the Company’s investigational calcium channel blocker envisioned to empower patients with paroxysmal supraventricular tachycardia (PSVT) to treat their attacks outside of the emergency department.

The strategic financing was anchored by RTW’s purchase of $50 million in convertible notes, as well as a commitment of $75 million in non-dilutive royalty funding, which, together, the Company expects will support the NDA submission and subsequent launch of etripamil for patients with PSVT. If approved, etripamil is intended to give health care providers a new tool to enable patient self-management. Etripamil has the potential to provide the patient with a greater sense of control over their PSVT, a condition marked by highly symptomatic, unpredictable, and burdensome episodes of cardiac arrhythmia. The Company plans to submit a New Drug Application to the U.S. Food and Drug Administration in the third quarter of 2023.

"Etripamil has demonstrated strong potential to offer patients a meaningful intervention for the treatment of PSVT outside of the costly and inconvenient acute-care setting and we are highly encouraged by the results of the Phase 3 RAPID study in October 2022,” said Roderick Wong, MD, Managing Partner and Chief Investment Officer of RTW Investments, LP. “We are excited to expand our partnership with the convertible note and royalty financings to continue to support Milestone’s effort to advance etripamil to a potential U.S. regulatory approval and future commercialization efforts.”

“As we continue on our mission of delivering this much needed therapeutic option to patients suffering from episodic cardiovascular conditions, it is a privilege to partner with RTW on these strategic financings, which we believe further validate the value of etripamil” said Amit Hasija, Chief Financial Officer and Executive Vice President of Corporate Development at Milestone.

RTW has extended its investment relationship with Milestone by purchasing $50 million of senior secured convertible promissory notes (the “Notes”) in a private placement transaction. The Notes are convertible into common shares of Milestone at an initial conversion price of $5.23 per share, which represents a 50% premium over the volume-weighted average price of Milestone’s common shares over the trailing 30-trading day period ending on March 27, 2023. Funds from the Notes will be immediately available upon closing.

The Notes will be senior secured obligations of Milestone and will accrue interest at a rate of 6.0% per annum, payable quarterly in arrears, with the option to be paid in kind for the first three years at Milestone’s election. The Notes will mature on March 31, 2029, unless earlier redeemed, converted or repurchased. Holders will have the right to convert their Notes at any time prior to the close of business on the second trading day immediately preceding the Notes’ maturity date. Milestone will settle conversions solely in shares of its common shares, except for payments of cash in lieu of fractional shares.

In addition, under the terms of the revenue financing agreement, subject to customary closing conditions and subject to FDA approval of etripamil, RTW provided a $75 million non-dilutive synthetic royalty financing commitment to Milestone in return for tiered rate, cash royalty payments based on aggregate net sales of etripamil within the United States. RTW will receive royalty rates ranging from high to low single digits based on certain annual sales thresholds, subject to upward adjustment if certain annual sales thresholds are not met. Royalty funds become available upon FDA approval of etripamil for PSVT, and satisfaction of other customary conditions.

The offer and sale of the Notes and any common shares issuable upon conversion of the Notes have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any other securities laws, and the Notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the Notes or any common shares issuable upon conversion of the Notes, nor will there be any sale of the Notes or any such common shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

Cowen acted as financial advisor to Milestone on the financing transactions. Cooley acted as legal advisor to Milestone. Gibson Dunn acted as legal advisor to RTW.

About Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone’s lead product candidate etripamil recently completed its Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and is in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit www.milestonepharma.com and follow Milestone on Twitter at @MilestonePharma.

About RTW Investments, LP

RTW Investments, LP is a New York-based, global, full life-cycle investment firm that focuses on identifying transformational and disruptive innovations across the biopharmaceutical and medical technologies sectors. As a leading partner of industry and academia, RTW combines deep scientific expertise with a solution-oriented investment approach to advance emerging medical therapies by building and supporting the companies and/or academics developing them. For further information about RTW, please visit www.rtwfunds.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “continue,” “could,” “demonstrate,” “designed,” “develop,” “estimate,” “expect,” “may,” “pending,” “plan,” “potential,” “progress,” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the closing of the transactions on the terms provided, or at all (including whether the closing conditions to the revenue interest financing will be met); future cash payments based on aggregate net sales of the Etripamil, the potential of etripamil to serve as a promising therapy for PSVT patients; Milestone’s ability to execute on the remainder of the PSVT program; and the sufficiency of Milestone’s current cash resources to support its operations.

Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of our clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT; or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation and Russian hostilities in Ukraine and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, including those related to the ongoing COVID-19 pandemic, and risks related the sufficiency of Milestone’s capital resources and its ability to raise additional capital. These and other risks are set forth in Milestone’s filings with the U.S. Securities and Exchange Commission, including in quarterly report for the fiscal quarter ended September 30, 2022, under the caption “Risk Factors,” as such discussion may be updated from time to time by subsequent filings we may make with the U.S. Securities & Exchange Commission. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contact:

David Pitts

Argot Partners

milestone@argotpartners.com

212-600-1902

EX-101.SCH 3 mist-20230327.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mist-20230327_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mist-20230327_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2310615d2_ex99-1img001.jpg GRAPHIC begin 644 tm2310615d2_ex99-1img001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" !" 00# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_.21$4._ M"\SQG8^*->_9 MP7Q;<6OBK7/VPM.\4:1J5OX?2_C:[N/A)K.JV6G_ !)US6TLH(TTY8H-;^%\ MMU]HBO+VTNX3+:^WE&0/.,OSK,/[7RS+/[&I8?$+#YEC88*ICJ=:=6"I9?&5 M*LL37C[/FE2M!R4X6E'62UITW451IQBJ:N^>2COLE=/FD]DE9M]S^K!0,*?; M(_'GL2/YTZODOQ%^VM^SSX+^.%Y^S[XW\?Z?X'\?6F@Z)K\;^,57P_X6OX=> MMOM5AIMEXQU*YM]#;77A:.3^R+NYMKN8/&MI]JGGCA/U'8:A;ZE9P7UC=VE[ M:74:RVM[8SQW=E35PN*PU.C6Q.$Q&'I8 MJFJ]&O6HSIT:].3E"-6E4DN2<)>S=G!RV=TK$SIU(*$IQE&-36,FFDUWOV_J MQHT5$"W]X>^1@$C&<=>_O4;ROO55XR,G*%AC(_B##!.>,@@]>*QYHW2'OB)H?B_4-9TWPQJ%OJ<^B) M";JYCAF.EN]RTR0""_1BLR[X'WM DR8*X<;A6M.C6JT9XB%&LZ$/CK.G)4H- MU'22E.SBI.2NE>[C:5M;')6S#!8>OAL+6Q5&GBL8ZL<-A95(/$U9T:N)%&">,# VD$8SU)X)QCI]?:M\5A5AG13JX:I*M2]K'V%2-6R4E!J M;48N,D]X]M>MCCRC.8YLL8E@\9@7A,2\-*GC49P3E5C.$H+FYX5 M)1=_=E)6DYJ*0]#CK@XST_'I_.N!^*'Q'\/?"+X<^//BGXO>ZC\*?#?P?XC\ M=>)I-.M3>Z@N@^%M(N];U0V%IYD*W-V;.RF%O#)/!&\I4/+&I+#EA&52I"E" M,IU*CC&G&*NZE2(;;P[XJ\,^.-&M_#GC/2)KZQMM0TS4[C0 MK76=8_XD6L127=KIFK+DH2A M)QFN622;4M-):K?R)J*^?/VE/VD_AE^R?\(/&/QQ^,>N?V)X%\&6,4MP+."& M^U[7=5NW,.F^&_"^DR7]E+K?B/59_P!WI^E6[(TRK+<23PVEM>W%KY-\!O\ M@H!^SI^T'^S)?_M>^'?%4O@/X%Z)>>)K3Q'XI^+EM:>!O^$>_P"$2O(K#5IM M6\S5-2L;:)[NXMK;3MM]--J-W<6]E:P27=S'$-*.79C7P*S.AE^-JY=+'QRR M.-IX>91O%-^\]EZL^W M**^)?V$M/- MEJFK6VJ:IX>U[3-.U@:/JVEZ!KLND:M;VT]G>3:7J%K TU]IUU:#E_V1?^"F M_P"R#^W#XT\1^ /V=_B+J?BSQ3X3\*)XTUG3-5\#>+?"9_X1Q]3T_1CJ5A=> M(-.L[6_2VU+4M/AO(+666:W&IV+2*@)+;UF MLN^L5U[^XK6;W MF?H%1117F&8444C9P<'![9Y_3WZ#WHO;5Z):M^2 6BHA)VX'..>"QQ_".,_3 MOT!Z5(#D ^H!_.LX585$G"5U).4=)*\5+E*NN;2_?[PU3LTUYM:/T%HHH MK0 HHHH **** "BBB@ HHHH JN VU2!AV7=E=PVAB2I&1@/C;SP"UU+4;KX?W^FQ1;;F:>VU7P)?+:V]T-.T;Q'J4$J+_ $\RH6"J6*!I M(S\N0P*L74J5!Q\ZID,0A4'>'3,;_P \O[!/_!9S]@W7Y?#7P&L?@J_['>J> M(?&#Z)H7AWPYX?T"_P#A+JGBK6M8CT;3I4UWP1IFF7=KJ7B;4FM+1M5\1^$M M/B34'2VU?6H5^Q3W'V?"N$EBLFXPE#@^MQ9*& P52GB:-2M27#M.-2NYXN?U M9JI4Y[1@JUR^U:?6=0 M?PSJL%O;-"+'P_:WQ,;L^MQ0OA??/COJT?[$_P"S5X?L?V?=.T7PW8^&O&WA MK1+73-;%WXBM9;#7IM5O-7-[W6:62"]M)H[GS!:2Q1-$B_F?_ M ,%&?V;_ !]%^U=??M-ZM\2=!^"GP[ET7X?>'?"OC:+6-&/"PL]974+>VMKF>:^UG6O#V@-:112/JNR^E6S^A/"W[6WA;6_V=O% M<'B[P]XW^,NG?#7Q7\-="E\8?$V]\'3^.]3U+QK-XN>#Q;;:%#X8U#POI6H^ M!H]#N7\-VUX=9EN&N+==1U>>83:I<^U4R?,,=D_#.:1QV)SW)\## 8+%Y;4I MPHX3 8O$8JO&CEOUR$8T>:3G'W:O/B(NLG.48.#7R^)X]X1PG%O#_ 4N(\!F M7'.;T*^,RO@6A*2S7'X/!Y?F>-JU9XJO['*LHPLIX'V4,?F>*G1GRUTJ$?9\ M\ON?]FW]I_5OBMX;TN[^)7A&/P#?:Q=)IOA_Q&UPFE>%/'NJF>=!IGA.SUO4 MY-?EOT2(E[*T?7K7,+5[JQF2>*2)+*XP[)\#? _P[XA^+?QU\#> M.O#OQ-O/B0OA3Q+X?UKQ#IGQ!+Z'XZT#P?I>IIY]Q';07.I^%-0T:(VWV6&' MPSK2Q/_9[\2ZKX=\8>,KFY\1%U?Q)\.? D:ZF+S M3YU2Y6R\9:GJS6/AFQAU2UG1]1LK6V\37$/G.J6\LTOF1\[R#+J'$&$I87!3 MSS$5Z"Q.*R?#X?$P6"J*M6A*E.4W*HX8>$8U5.5J=9I*+Y'I^7YSQEF^:<(\ M?XSC'%8CZ.];*LXP64\/8[,IX#/<3C:.(R>OF%2K.NN3*\2L1BJ,<-3J\,/, MJ]+#5$X4G7FIK]"_"-CIGQV^#O@J_P#B"LMW?:E#)J!6?FS\*O &A_#?Q'XUL= \6?\)+NL=+:;00=.DU M?1S"=3FCBOS9S1VZ27I+QV:#3[&;,;M=>>/+D3PI_&\7CGX2^"-+\(W&I?!. MSUOPU%XBT]/!KVL]GI:'5-=T:X\+7-G]DT"XGTEWL;F\:?3;G3]4M;N&.&?3 MU4-".C_9D^&GB?X9R>.O$'B34M'U3P]K6F:;<6?B#3[VZE6Y%C-JL^J37=E? MVT6IV5S;Q2Q-&LOQ>(\55>IC M%E:J8?'_ %2M)/$6SZA]6C.JT\-)*=&M;+Q'J%K#I]KIES=7L; M6VIZ7'>02ZJ?LK,MQ:Q?9[5'8 2S0$[Q]GP*1DMG. H]"H9R"/<@C/T]#SVKZW?[C?[K?R-?(_P"WE_R9 M)^UQ_P!FV_&G_P!0#Q'7#E&N>Y%"]E+-\M=U\49+-,K@I1;NKI5Y/525U%M. MS4OT>BE[6E+M4AH]OBB]5\ON/\^/_@F3^VEJO["G[5GPY^+\NHW\'PSUBYL/ M!'QTT>SM;C48]:^%>MW5NFJZA)IL-S$UYJ_@J[%EXN\-B".6[FO=+FT:*!QK M;++_ *4?A+QKX4^('A7PUXW\$:[8^*?"7B_0=.\3^%?$&B2_:],UWP_K=E%J M&DZGI]U&A62UO[*>.6.1=KJ'*R"-PRC_ #?OV)OV(KC]L#]F?]N_Q1X.LKK4 MOC+^S3X6^ GQ/^'&EV@,Y\3Z)?7'QE_X6?X'.G-N:!X:TC5]!WEII MM>\.:'HT+P1ZU<7-I]8_LM?\%J_B1^SK_P $[?B;^R;IT&LWWQ4LP^@_LT_% M.(6[0^!/ GCB=Y?&,6I/- EV?$G@.6\U76OAM=W%C<6[F6'6+JKV,;5XQBJL8)*'LTDU*UKIJ*NWS-6;5C>_P""\_\ MP4'TO]K7]H+2?@?\)?%+:Y\!/V>+S4=,N;RQD?\ L7QO\=8[[Q!H'BKQ%83) M)+9ZSH/A?2?(\'>&+X&)+R_O?%FHZ??3Z1J5H;S];O\ @E#\$_A+^T5_P0X\ M;?!WXZ^(+CPE\)O%_CSXNS>-?%]KK6G^'I_"EAX5\9Z/XSM?$ZZSJ]M=:59) MH&J^'+#5IFU.VFT^:"TD@O4,$TI'\WB_L7:AX9_X)DZ[^W+X]T[4+75_B-^T MAX ^%7P/2YO)H%OO 2Z7X[O?'_CKR6>&&_L?$WC*P@\.Z&]VK&"V\#ZQJ%HL MEGJVE26W]"__ 3D4/\ \&\O[2Z,,JWA/]K\."%*LO\ 8VI%D96!4JX&QAW5 MFQR M%_ WQ,U'P+H,>A^&]4UY;?4-73Q7XCU'6=4U'7 NIO96$>FZ7IMG;2J_Y._\ M&OY5/VQ_C;(W1?V5=0);&2 WQ6^&)8\#=SM4GV49SM&/9/\ @WC /[)G_!3[ M(!!\$^%I& 54!,OPJ^,\C@! NU-TC!%7"QIA(PJ@"OG_ /X-IM=T_P +_M1? MM&>)]7=XM)\.?L=>(]?U1HUW.FG:-\2/AUJ-ZT8)&66UM92@R,G SWKGS+!9 MKA68_".M"E0I0BZ5;%1I4H4H4/W M4(QDG.3G*:BE&&:QM? M%7Q]^,'@+X1:'J,T]MI5UXZ\0V.A3ZW?5='\+>(+:;Q+ MI=LC1)]KU+PI=_9/$MA9/)-%'%>W>DPVDTLBQQ3.^0/\^^V_:-^#7[;/[87B MSXX_\%*OC[\9=#^$$EQXDUCP1X=\ Z%J?B;Q%!X8U#Q7=ZOX2^$/A:&QBN-( M^'O@K0?#=]/J6LZG_9>I:MJD=G)8R_;M5U*_UBSY7XV?%O\ 9O\ V9/VE/!/ MQ[_X)5?'#XM:3INAZ'<:G:GXB>';O2?%7@77K;SM/UKPQ+K&KVRZ?X_\ ^-= M+2ZBN=/N+.0:7Y6J:/J$UZ=3TR9/GJ'@-'E>3U\USN?$BRF..>/H[7FO38_T;OC'^T'\$/V>O";>.?CE\5/ _PH\)^?]E@UOQUXAT_P]:ZA M>E&E73M(2_FBN=:U-H$>X73-)@O;\VR->&=/:_OH9KJ/2IO#-DC9-*\0#2M'36;K4KC4-(O?'GAK59WTRSN=3TFYLKZQD^6J^'& M299P-0XFS;->(*V88W X^O2GD61X?,>'LJS+"5'AAHUJE3$QG.$Y1C'#2E34HN<5%U=FFX_&D MTDV]D>7_ /!>W_@H#\1/"7[0GP5\$?LE_M>>)O"EKX)T/QSH_P :?#GP2^*M M]HZZ%\1=%\=:7I[Z-\0X?"FJ0F/7=*AL[VTET/7R MW[QV,TVZ_9+/%=AXFAT**V\*>(?%GQ5N]8NM#\+3Z79:<\FD6][XEOOL@UF6XU(0VJI+ MJ$[3RE?W6^ ?_!+#]G3_ (),V_C;_@H?!\7/C+\3IO@]\ OB!KG_ @VM6?@ M'2=-U&UU?PU;W=[96UWH?ANWU&._U&XM;73M-N);Q;2RFO!>7HN8HF-?0<69 M#P(_#/@#$83,\;0S;%<.X_\ L&5#(Z53$<09M/&483IYTZ-/#SPBPV-K5J&' M]O4E4KX2G2JTY4XU.6&E>EA5@Z'))QFUS)M*\Y-6<6^5:+6UW;2]S]N/CO\ MM5?LY?LQ:)8^(/V@?C+X"^$NFZK++!HX\8Z[;:=J6MR6[0I=C0]#!EUO6ELG MN+=;Z72].NXK(SP_:7B$J%F? ;]J[]F_]J#1-3\0?L_?&?P%\5]/T258=;C\ M):W!=ZKHLDG^H_MG09A;Z[I27?)L9M0TZVAO@K&TDF",1_%!^PC^Q9\7/^"W M_P"T#\;_ -HS]J/XP^(-&\(^%-4T"U\::WX3M]-NM;U37/$5O=W?A_X9_"RV MU^SU7P]X(\'>"/#UG''=W%UIFJ75OI&HZ,;>SU+6_$FLZUI<_P"WS^PO\4/^ M"*?QN^!O[3?[+/QD\4ZEX/\ $'B.\TWPIKWB7^S[7Q1HOBS0[9-7U7X;?$*/ M0[73=!\7>"?''A.RU5HU.E6DE[8Z5KNBZGIEG<06VK7W#+PIX:AF<>"9<:-^ M(OU/ZW/ 2RVK2R%8OZNL3#(:>/DG5J9G6HRIU54O"E3]HZ,J7M*;C(C@*$IO M#_6$\4U"<8KX)1E!3<=8MW:>DD_D]C^X'XD_'KX*_!R\\$:?\6/BIX"^&]_\ M2O$D?@_X?V7C7Q1I'ANZ\9>*93 $T'PY!JMW:R:KJ9:[M$:VM%D=)+NUC?:] MS"K^#_&3_@HO^PW^S]XS;X=?&']I_P"$W@GQU"46^\)WGB%=2US1GE8B.'Q! M8:'#JDWAVX%X+ MGPY:?$Z#QOX_M[ SL;[PMK&H^#_AQZ\+Z\EYI[72RB-Y]*_M. MWCG$43)K_L_?\&[ME\;?V5+;XV_$S]H'Q>_[27QI^'UM\8/ ]OHQT>_\!:5J MGC;0(/&/AS3/B7J'B?1M2\8>-]2U:^U6.;Q;KUIJ&@162?4O) MRS@#A/!<-9%Q%QQQ9C\DEF>;9YD.(RW+\FEC:E#,LIS*.7*2Q3FZ-/#QG3Q4 ML3*:J.*@G!\J?-DL'3C1H5:U25/VT\1#6UKTJBC&UDVERW&/B%X'U^!KC1?%W@O6].\2^'-4BCNYK"X^PZQI%Q=V M%Q+97UM _A/X M>N)I[:POO&WB+3]%DU>ZM1 UU::%I]Q-_:6O7EHEU;S7=IH]G?7%M!,D\\4< M)+C^1C_@V1_: \8V?Q0^._P,U/Q/J8^#E[\&H?C58^&=2N;N^TSPIXJT+Q)X M&O@C:W?B+4?"7A_P !>'+WQ)KND>#V\227GACX2>!= M.TZVFTOP%H=GI#M=^)?%*Z9?7MW-HEPD;ZAXEU9KW3?0PW@QBGQ7Q)D^*S&O M/*N&,KPV!P<5RT\UQ--N?+4E0A3J5)PWM4CS**=FN:VGEH^NG^@1\ _VTOV4?VHSJ,/[/OQ]^&GQ M5U#2+9[W5="\,>([67Q/IVGH\,9U.]\*WIL_$=MI1DN;>--4FTM-/DDGA1+E MFD0'Z:219 2N& .#U!Z$$$5_F=_M!?$[]E_\ 9V_:!\#_ !M_ MX)6_'7XT>'4T33K^\:#XA:?J.A>+/ /B+3KB:&^T^R\0ZBJVWCKP)XTLU>"] MT#5-.U&-)++5X-8O=4L]6TV.Q_T9_P!GSX@S?%KX#_!;XK7,$=K<_$[X4?#O MXAW-K#'Y,5K=>-/!^C>([FVCBRQB2"?4I(DC8EHT14))7)^:\0N 8<(4.*PO ML%2J0Y_958W]]>\I6V;6FEGYGL%%%%?FAQE*<2E4\M4+B1=C.S!4(+;6(0H9 M%#A?,C+INCWA2S!4?\2/^"76K?\ !(S3M)EM?V.]6\&VWQ1U3Q)?#6[?XR7G ME?M'WGB;]Y'.(8?&\J:@+66">1;6'X7QKX0F\Z=%0ZNFKJG[=NS*$(YRZ?*" M!N.YOE'&3SR., \N40,Z_P ^/[ G_!&_]@O0K+PM\=+7XP1?MD>(=)\;1^*M M%\9>&O%]A;?";2O%.D:E;ZYIMM9>&/!&LZF+R\\.ZHT5Q+IOBWQ+JEL9DL)+ M_0H)H(RWT_#\\HAD?%"S7-N)LMY\-E4\%ALCPL:^7XK%4ZN+<*6;QJRI4J-& M/,I4G7JRKJS4FF[NRE:R2\VTM=I7=J/[8?AK M]M'6?^"A6O\ _#.?A[Q]K.@7OP[^'EG=VU_ID&J?!2]L#I]Q)JEKXKLO'<%;E[Z66YF:WUB*>6XAL)&U*\MTF^M_$G[.OP3^!GP&U76?C7HNC^%KSQO MXP^'-[XTTWX::KX_F^&FG^.= N_$5QX;GLM/FNY_%FD>$I7U6\;Q;9>';A]\ M4:QZ'9"-41_"/VN/^"@O[2WP _;DNO@[\/-"T3XD^"3X4\"7MC\,IO"%W?>) M-3U'7;-KC4YM#UOPTX\3#4+J27R$>6QU[3;1EC2/19&9S7Z+_$?X:ZW^U[\" M/#&B^*=%\4? C4=6\1^'?%.M>'?$D.BZUXET6'1WO!<:=&VCZQ=Z=#>:A#>> M?83W4HN[=<1ZGI-G<*UI']'C\QS;#93PE2QCR[ Y)7P.%E5J9/CL17S+&X>E MB,0Z=7'X;$U(PHXRE9N"CA:E"FU3]G73E*FO/S+A[),QQN29QC\DR6>:9/1Q M,,JS^.&PU//\MCF%.>'Q4LLSJAAYYGE-=TFU*M0AB9-22=.5W&I^9?P_G_:# MD^/_ ,%;6"WT6;X-Z=\1/!SV _9Q^;X06^G&[ NI-5;18CKCZA(J70U1?BBR M:[E)U*Q03?-[9+J>EZ;IU]IW[1%_X1M_ L5Q=W<5G\7)I!XJ%M/))F;X=1Q^ M;\0CJ4L NXM*&BW!TV6XGA+@B,*/T)^#/[+GPJ^!BS77@JSU:77+VR%A?^(] M>U2?4]6O+'SS.>+GF=+"0A MD6,RS$X/"XZC2JO&T*'MJ4,)0QN"R.-51IN4H^_-7Q.NH:A?1V\FK)/I?ER0J M%B1G QOV.Q\9%\8_%V3XR6_C.WUE++PUY#>+H[BVTUI5O];ANTT-(TBT&*V2 M-8ECBT1?L<<+0/#Q.A;T&2'QE^R5^S;X4\.>$_ ^N?'O7O!]D^D7%OX;M/[, M=XKBZO=4FUJZTZ*?5=6&G6SRF VNE6^JW\Y&2+:'S9X/)?V+?VDOB#^TAKOQ MBT[XFQ:.-+T+3]#M[;PSIFCRV$&G'6IM;M=7L;QKUY-8GG%K;V]M?6MU=2BV M$9EA16G/D\\:.)J\/\6U\)@(8TWCXU$H8A\V.S&%2C/ MVDJ6/P^#HSFY-UN9SC#Y>MC\LPGB-X'.79GFV8.C&FXX&,'&H_8/%VL?LRW?Q0\" M7NB7OQ*N/%^BQZ$/!$YEN4U(:C:IIK>)_P"Q)#HZ:<+D*MQ%K2?VA,C2I!M= M65_LFSR3(['+-MSRV I),2[22H*Q%58IC)7YLMDG\_[K]E+X)_#SXB_#;Q7X M9\8_\*ZN[7QOX6'0/#5MJ5Y#KW]HZCY9MK;=>: MG%;2\+I\&T)7W[8-(Q?>H0;1M4_?8B213(<94K( '0J2N&(&,<^#GLL%..6+ M+>Y>\)AN$*U&I0Q6%GD,:DL1F]64EF=;,ZE67/[//DD*%_9J^-,I8_PHOP]\0.Y)QPJC M<6/IZDU]=GH>U9&MZ%I'B32=3T'Q!IMAK>AZWI]YI&LZ-JMG!J&EZMI6HV[V MFH:;J5A=)+:WMC>VLLEO=6MQ%)%-#(\;JRL0?%P==8;'8+%.#G'"8O"8MQ32 M]JL/B:-:5"^\?:1I?%=)-I[I6_5(R<)TZD5=PG%VOT33OKIHTC^0#_@U=<'Q M)^W6T95_+\*?LKKNC9&(9]2_:*DC"-\RMNB<2H5WH8Y8GR4GC+R_MI_\$,O& MOQ1_X*9^&=0^%]D/#_[+7[1NKW_Q-^)GBW1="6WTSX*:EH,%IJ/Q+\,O;6/M(T33;:W@58;:VLK*+3M-LH MHU2,NMM:VL>YX(3X/_P3BEC_ .(>?]I7YT(/A+]L%0RME21I=^K89R6 M\Z2V_P!LT37+2[TZYDM;KR6LY;F&6XCF0RQ.C'&OA1\&_ G@2]^$O@_X M5?#[PM\+]4MM9M[OX>^&O!&@Z3X#U&TURTD.NPWOA?3K!-%F@UB%MFHI?VJ) M?HX$R3;\5YN&X[I9?P3@.%Z^5XNK7P?'=+C"69TL3"+KTL-SXW%4IQJ-SE5D ML+4G3K2E*49\S?O5%)X0QD7A_J\H3DE-8MKEFIPI6E.52I!7E3H\D93=2IR1 M482<7.:5.?\ *)_P;P,C?LE?\%/G#HR'P-X3^99%89'PH^,>?NL?E*X=&QME MC*RQEHV5C\^_\&T>C:;XJ_:B_:)\-:J!/I'B3]CW7] U..-E#2:;K7Q'^&EC M?A"<@*UIJ#*'&5\SSHES/;SQ1_V:_#7X"? GX.Z7XAT;X0_!GX6_"S1O%31? M\)5H_@;P%X<\(Z;XD^R6TUE FNV.B:796NK16=C$M3U;35NKB\%G MJ-_H&FZ;=7EA]NA2\-K<74D7G+#-)O\ @C?^UY\6_AC^UK^R M#HWQL^'6MZI<^%=+'Q!\'^'CJ.H>#O!OC+4D\-_&7X*:EXQ\/:WX:UZRU7P_ M=&_U/2K/4-/CO)VT[1O$&M>'=8T=HK?]4_!?_!7S]@[XQ?M+?"+X*?"C_@ES MX4\1>"/'GB6WT'Q-XNN_@_\ "_5/B=IDERMW&^H^&O@[X)\!>+IM>TOP[.? 6K>)/&NBV>D^%+G3OACX6M;RU\,^#6\,>#O$VDV>C:_+?R6OB M&>\.@^)?!]]X*T;1+&_M)-1N-4TS3XOY.KI_A5XD_P""C'PAG_X)3>'OC5H> MC3_$3X;:I\)O#?BJ74=1\8>&_%D>KVTWC:VL[V^U[Q+K\OPVTZS5/[7E\8^) M-1\OPS)KEKXBO)- 2%A_H2_&7X _ O\ :,\.6WA?X[?!_P !?%[0[&_GDTBR M\>^$]/U^XT2YNV%KJ5[X?NKR#^T]#N[N"T1;F]T":RFN80%G9H" >2^!G[(/ M[+7[-$UUJ'P _9]^%OPMU[5T:VOM=\-^%+6'Q/>VMR;:>XTZ;Q-*6: &(9CA'Q#R'A#A[$*CD'$N+SNO@<=@\PPD^)ZE3A+-L M37CC::S#,.'ZN'Q%5XC#PQ-.#I4JBIU_J\W.O+ZS.<"=2[P:9?7 M,-M>(_ MBEXN\6>$;F?P;XAT?X2^*?$;2Z-X(T2VU(>--'M9?"K1C4=3\0>"YFNY]/@F MT+R[J4P?T#_%[X0?"3]H'P=-\._C3\,_!?Q4\$W%Q'>S>&/&_A_3=>T_3]2M MXIX;75;:"]WW.BZQ;6M]>V%CJFGFVU*"&YN(X)DBEECFX7X(_LE?LO\ [-;R M2_ ;X!?"WX6WMT)!?:MX1\':?8^)+FUFV1RP7'B62VN?$3V9B7,5I_:8L)'E ME,<+R3,S>;#CC(,1P7P_P_G'#V;U>(>$:F8T.&,TRW,:&%P&%KXK'K,<+BL9 MAJL)5,1#+\:HSBJCG&M%1A%^RE& UC,-4H2I2H\]2$9SIU(5J;IQY:E:$YN4 M:M2/+%T:D&I)+]VVKIIO^,?]AO\ ;-^+O_!#S]H;X[_L[_M,?!KQ)XJ\+>*- M4T(>)M*T&]M]%U.VU7P@-5L]+^*WPIOO$EI::+XZ\-^,_#FK):WNG3ZII$<\ M<&FW"^(M/U'0]5TS4IOV[?VZ?BK_ ,%L/C?\"/V;OV:O@MXL\.^$O#?B6:\T M'1-;NK?6O$>H>)O%,EAX>N?BA\1W\/6]_HO@3P-X'T*6\A#G4M6@ATV]UC5K MW697O4L-,_M4^-O[.OP(_:3T2#PQ\>_@_P" ?B_HFDW N=*L_&7ARTUF32;B MX6!GNM$O)X5U#2)+KRXC=OINIP-/L@%S]H,<:PO^!_[-_P !OV:O#FI>%O@) M\(/ /PBT75YEO];A\#^&(-'?6+N!?)@EUO43 ^HZQ+;P,8+=KZ]NIK>(F*S\ MJ,E*]ZGXM\*0S"CQIB.#,9+Q.C#"4Z>;5\?S<,RQL\+4PDT& MGS^(]0T#X=^ [+7O$LFFQSW*64WB/5#JNM7%C;2O!81ZC-:1$VL0S_4O^Q@L M8_8T_91(VX7]F/X%-E0I7 ^%GA4 @KD'IG*D@@#!/%==\6O@K\$OCG::/I?Q MJ^$OPX^+-CH%S/=:'9?$7P3X;\;V6CW^HP"VO+C1XO$%AJ$5E<7<,=HES-!% M%+<0_8P^Z-AM])T>UT[0]'T[P_H&DZ?I.AZ+8V^CZ1I&DZ?;V6E:3I&GP):: M=I6FZ=8K';V-C8V26]G964=K%;PPQ)#!'Y845\'G?%]3.N#N%^&IX#$QQV29 MQGV;YACZ^(HSIYC4SG%2Q2C&;Y5R3C'^&__ (-AH+#4OVLOBEIU_'#= MV-_^R9K5K?VTC*T4UK-XW^'<5_#<*#N'GQ3>3)N*LX$Z@E[>81^!?";7]6_X M(T?MI?$WP#^U9^RIHGQV^%WB&:^\,V\'C_PKX:N9O$O@S1/%L5YX8^-?P&-)UU=(N;F+R+B\T*XNK5KS0=0GAS#-J6CW%EJ$L+&"2Z>#$8^\K>,& Q7 M$F>8RMD.:5N&>).'\ER3-LLJYO\ 5LU57),*\-2Q=#'X&>'G1K%2% M.$:=6JVU&?8LPC[:4JM+VU*M3I0J0C)T[*G%J+3BXIWOT#O&GB?1=$\7Z_=_!_X33_$72]-U6'_AYIO@*YU;3/#%W!KNJ0^'H/#/@SPYH5RUBEU>&R M\2^%(;+1=$AGEM+76M%$UM:B_ME?$^"'[%G[*?[-EW<:E\!_@%\+OA;K-W;3 M6%WXB\+>$].M_%-SIMS);37.E3>*;J.Z\1-I-S+964]SI8U-;"YGM+>2XMI? M+"GU'6O@O\*O$NM6OB7Q%\.O NO>);'5XO$-GXAU?P?X>U'6[/Q%!IFFZ+%X M@L=5O-.FO]/UN/2-&TC3(]3L;BWNDL-*TRS$GV?3K..'\_XKSOAK.,7A:>2Y M9Q-EV5X+#5(169<02S7'8K&U&I/%36)Q%?"4*3UA6AAZ5*M5CROFO&-^2M5I MSE^ZC*G36T)3E.WS;=GOLNQZ86Q@# X'!!S^E%*5R>H_('^=%?"RC6N^7V'+ M?3FC-RM_>:=F^[1SZ>?X$+JP",H;Y73(7DX+\C'0@@X;=@*"7RI0$?S%_P#! M.K_@BQ^UM^SO\1K;XI_$K]J?5/@UILGBZ/Q1K_PJ_9Z\5>([S_A/(;35CJ5I MH?Q"U34++0_"%[I]TK/;ZE;W7A_QW&+"6XM;&]M;^YAU'2_Z?**^ERCB/-

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end

XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Mar. 27, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Mar. 27, 2023
Entity File Number	001-38899
Entity Registrant Name	MILESTONE PHARMACEUTICALS INC.
Entity Central Index Key	0001408443
Entity Tax Identification Number	00-0000000
Entity Incorporation, State or Country Code	A8
Entity Address, Address Line One	1111 Dr. Frederik-Philips Boulevard
Entity Address, Address Line Two	Suite 420
Entity Address, City or Town	Montréal
Entity Address, State or Province	QC
Entity Address, Country	CA
Entity Address, Postal Zip Code	H4M 2X6
City Area Code	514
Local Phone Number	336-0444
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Shares
Trading Symbol	MIST
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	true

XML 8 tm2310615d2_8k_htm.xml IDEA: XBRL DOCUMENT 0001408443 2023-03-27 2023-03-27 iso4217:USD shares iso4217:USD shares 0001408443 false A8 00-0000000 QC 8-K 2023-03-27 MILESTONE PHARMACEUTICALS INC. 001-38899 1111 Dr. Frederik-Philips Boulevard Suite 420 Montréal CA H4M 2X6 514 336-0444 false false false false Common Shares MIST NASDAQ true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://milestonepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince, dei:EntityIncorporationStateCountryCode - tm2310615d2_8k.htm 21, 23 tm2310615d2_8k.htm mist-20230327.xsd mist-20230327_lab.xml mist-20230327_pre.xml tm2310615d2_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2310615d2_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 25 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2310615d2_8k.htm" ] }, "labelLink": { "local": [ "mist-20230327_lab.xml" ] }, "presentationLink": { "local": [ "mist-20230327_pre.xml" ] }, "schema": { "local": [ "mist-20230327.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 5, "total": 5 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mist", "nsuri": "http://milestonepharma.com/20230327", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2310615d2_8k.htm", "contextRef": "From2023-03-27to2023-03-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://milestonepharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2310615d2_8k.htm", "contextRef": "From2023-03-27to2023-03-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://milestonepharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001104659-23-037370-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-037370-xbrl.zip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�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end